Search:
Tokushima UniversityUniversity HospitalCentral Clinical FacilitiesTokushima Community Medical Support Center
Tokushima UniversityUniversity HospitalClinical DivisionDepartment of Internal MedicineHematology
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Book:

1. Kumiko Kagawa, 前田 悠作, Masahiro Oura, Kimiko Sogabe, 藤野 ひかる, 髙橋 真美子, 丸橋 朋子, 岩佐 昌美, 宇高 憲吾, Takeshi Harada, Takayuki Ise, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shusuke Yagi, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and 藤野 ひかる :
Analysis of long-term survivors with cardiac AL amyloidosis,
The Japanese Society of Hematology, Oct. 2017.
(DOI: 10.11406/rinketsu.58.2197,   CiNii: 1390282680011466240)

Academic Paper (Judged Full Paper):

1. Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masahiro Hiasa, Yusuke Inoue, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Mayu Sebe, Rie Tsutsumi, Hiroshi Sakaue, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.,
Clinical & translational immunology, Vol.11, No.1, 2022.
(Tokushima University Institutional Repository: 117260,   DOI: 10.1002/cti2.1371,   PubMed: 35079379)
2. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, Sou Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma,
Haematologica, Vol.106, No.5, 1401-1413, 2021.
(Tokushima University Institutional Repository: 116529,   DOI: 10.3324/haematol.2019.234476,   PubMed: 32273474)
3. Motoki SUGASAKI, Naoki TOKUNAGA, Akishige IKEGAME, Takayuki NAKAO, Masahiro Oura, Hirokazu Miki, Kojiro Nagai and Tetsuji Takayama :
A case of congenital prekallikrein deficiency discovered by preoperative screening,
Japanese Journal of Medical Technology, Vol.70, No.1, 132-137, 2021.
(DOI: 10.14932/jamt.20-5,   CiNii: 1391694356262403200)
4. Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis.,
Internal Medicine, Vol.60, No.11, 1753-1757, 2021.
(Tokushima University Institutional Repository: 116536,   DOI: 10.2169/internalmedicine.4916-20,   PubMed: 33456032)
5. Mamiko Takahashi, Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.,
The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 196-201, 2021.
(Tokushima University Institutional Repository: 116021,   DOI: 10.2152/jmi.68.196,   PubMed: 33994471)
6. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Ryohei Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.,
Cancers, Vol.12, No.4, 2020.
(Tokushima University Institutional Repository: 115041,   DOI: 10.3390/cancers12040929,   PubMed: 32283857)
7. Kengo Udaka, Shingen Nakamura, Shiroh Fujii, Ryosuke Miyamoto, Naoko Matsui, Shiyori Kawata, Taiki Hori, Junpei Murai, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Kumiko Kagawa, Yuishin Izumi, Masahiro Abe and Hirokazu Miki :
Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma,
International Journal of Myeloma, Vol.10, No.1, 8-12, 2020.
8. Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe :
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.,
Oncotarget, Vol.10, No.20, 1903-1917, 2019.
(Tokushima University Institutional Repository: 113359,   DOI: 10.18632/oncotarget.26726,   PubMed: 30956773,   Elsevier: Scopus)
9. Yuko Miyakami, Shingen Nakamura, Masahiro Oura, Yasunobu Okamoto, 高橋 真美子, Kimiko Sogabe, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hisanori Uehara and Masahiro Abe :
De novo CD 20-negative diffuse large B-cell lymphoma developed with sustained fever and markedly high C-reactive protein level,
Shikoku Acta Medica, Vol.74, No.5-6, 193-200, 2018.
(Tokushima University Institutional Repository: 112987,   CiNii: 1050845763422780928)
10. Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe :
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.,
British Journal of Haematology, 2018.
(Tokushima University Institutional Repository: 113393,   DOI: 10.1111/bjh.15673,   PubMed: 30474853,   Elsevier: Scopus)
11. Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe :
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.,
British Journal of Haematology, Vol.180, No.2, 246-258, 2018.
(Tokushima University Institutional Repository: 112752,   DOI: 10.1111/bjh.15033,   PubMed: 29327347,   Elsevier: Scopus)
12. 山口 純代, Shingen Nakamura, 住田 智志, 前田 悠作, Masahiro Oura, 高橋 真美子, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Jun Kishi and Masahiro Abe :
Development of adult T-cell leukemia/lymphoma during immunosuppressive Therapy for human T-cell leukemia virus type 1 associated arthropathy,
Shikoku Acta Medica, Vol.73, No.5,6, 301-308, 2017.
(Tokushima University Institutional Repository: 112059,   CiNii: 1050001338847982080)
13. Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by hyperthermia.,
Oncotarget, Vol.9, No.12, 10307-10316, 2017.
(Tokushima University Institutional Repository: 113059,   DOI: 10.18632/oncotarget.23121,   PubMed: 29535808,   Elsevier: Scopus)

Review, Commentary:

1. 山口 普史, Hiroshi Bandou, 新谷 保実, Hiroaki Yanagawa, Naoko Matsui, 重清 俊雄, 田邊 舞, 高岡 奨, 飯間 努, Masahiro Oura, 喜多 秀仁, 戸根 沙織, 野田 和克 and 森住 俊 :
意識障害患者の鑑別診断における詳細な病歴確認の重要性,
日本内科学会雑誌, Vol.104, No.7, 1495-1503, Jul. 2015.

Proceeding of International Conference:

1. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Takeshi Harada, Yoshiki Higa, Kimiko Sogabe, Masahiro Oura, Ryohei Sumitani, Tomoyo Hara, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
Mechanical unloading promotes bone destruction and myeloma tumor expansion,
Cancer and bone society young investigator symposium, Online, Feb. 2022.
2. Hirofumi Tenshin, Takeshi Harada, Yusuke Inoue, Jumpei Teramachi, Masahiro Hiasa, Sou Shimizu, Emiko Nakaue, Kotaro Tanimoto, Yoshiki Higa, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Targeting SLAMF7 to disrupt myeloma-osteoclast interaction: elotuzumabs ADCC activity with Th1-like gamma delta T cells towards osteoclasts and myeloma cells.,
Cancer and bone society young investigator symposium, Feb. 2022.
3. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Novel strategy of elotuzumab and zoledronic acid with Th1-like T cells against myeloma,
18th International Myeloma Workshop, Wien, Sep. 2021.
4. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Induction of elotuzumabs ADCC activity by Th1-like T cells towards osteoclasts as well as myeloma cells,
EHA2021 Virtual Congress, Jun. 2021.
5. Hirofumi Tenshin, Takeshi Harada, 井上 雄介, Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Tomoko Maruhashi, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The anti-SLAMF7 elotuzumab enhances ADCC activity with Th1-like γδT cells towards osteoclasts and myeloma cells.,
The European Calcified Tissue Society 2021 Digital Congress 2021, web, Mar. 2021.
6. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Takeshi Harada, Eiji Tanaka, Kotaro Tanimoto, Sou Shimizu, Masahiro Oura, Kimiko Sogabe, Masahiro Abe, Toshio Matsumoto and Itsuro Endo :
The novel therapeutic approaches with TAK1 inhibition against the aberrant NLRP3 inflammasome activation in rheumatoid arthritis,
ECTS 2020 Digital Congress, Oct. 2020.
7. Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma,
61th ASH Annual Meeting & Exposition, Orlando, Dec. 2019.
(DOI: 10.1182/blood-2019-127679)
8. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Ashtar Mohannad, Kotaro Tanimoto, Soh Shimizu, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The role of NLRP3 inflammasome activation in joint inflammation and destruction in rheumatoid arthritis: novel therapeutic approaches with TAK1 inhibition.,
29th Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting, Oct. 2019.
9. Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe :
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy,
17th International Myeloma Workshop, Sep. 2019.
10. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka :
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.,
AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
11. Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis,
60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
12. Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.,
Esmo asia 2018, Nov. 2018.
13. Noriyuki Shimizu, Masahiro Oura, Sachiko Chikahisa and Hiroyoshi Sei :
EEG delta power in NREM sleep is enhanced by refeeding after 24-hr fasting in time-dependent manner,
36th International Union of Physiological Sciences, Kyoto, Aug. 2009.

Proceeding of Domestic Conference:

1. Shingen Nakamura, HORI Taiki, Masafumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, 高橋 真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada and Masahiro Abe :
Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia,
The 47th annual meeting of Japanese Society of Myeloma, May 2022.
2. Takeshi Harada, Ryohei Sumitani, Asuka Oda, Inoue Yusuke, Masahiro Oura, Kimiko Sogabe, Kimiko Sogabe, Tomoko Maruhashi, Takahashi Mamiko, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Therapeutic impact of targeting RNA editing enzyme ADAR1 on myeloma cells with 1q amplification,
第47回日本骨髄腫学会学術集会, May 2022.
3. Kimiko Sogabe, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, 小田 明日香, 井上 雄介, Ryohei Sumitani, 丸橋 朋子, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Resumption of myeloma cell sensitivity to proteasome inhibitors by PIM and Akt inhibition,
The 83rd Annual Meeting of the Japanese Society of Hematology, Sep. 2021.
4. Hirofumi Tenshin, 寺町 順平 日浅 雅博 小田 明日香 原田 武志, Masahiro Hiasa, 小田 明日香, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Eiji Tanaka, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
NLRP3 inflammasome aggravates osteoclastic bone destruction in myeloma,
日本血液学会学術集会83回 Page 83回 Page OS2-4B-4(2021.09), Sep. 2021.
5. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Takeshi Harada, 小田 明日香, Masahiro Oura, Kimiko Sogabe, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
Extraosseous dissemination of myeloma by mechanical unloading,
日本血液学会学術集会83回 Page 83回 Page OS2-11C-3(2021.09), Sep. 2021.
6. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Expansion of γδT cells by CELMoDs and enhancement of their anti-myeloma effects by elotuzumab,
The 83rd Annual Meeting of Japanese Society of Hematology, Sep. 2021.
7. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Development of combinatory treatment of Th1-like γδT cells with elotuzumab against osteoclasts as well as myeloma cells,
第46回日本骨髄腫学会学術集会, May 2021.
8. 石田 卓也, Hirokazu Miki, 髙橋 真美子, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 岡本 秀樹, Naoto Okada, 矢野 由美子, 高橋 真理, Tetsu Tomonari, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Keiko Aota, Hiroyoshi Watanabe and Masahiro Abe :
HIV感染血友病患者における臨床的特徴と今後の課題,
第262回徳島医学会学術集会, Mar. 2021.
9. Maruhashi Tomoko, Shiroh Fujii, Kumiko Kagawa, Nakamura Masafumi, Shiyori Kawata, Makiko Mizuguchi, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takahashi Mamiko, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Masahiro Abe :
造血幹細胞移植(allo-SCT)が奏効したMLL遺伝子変異合併CML急性転化(CML-BP)の2例,
第43回日本造血細胞移植学会総会, Mar. 2021.
10. 清重 尚希, Ryohei Sumitani, 水口 槙子, 中村 昌史, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, 賀川 久美子, Masahiro Abe, Shingen Nakamura, Hirokazu Miki, 曽賀 愛未, 一宮 由貴 and Yuri Yamamoto :
急性転化をきたしたAYA世代慢性骨髄性白血病の1例,
Shikoku Acta Medica, Vol.76, No.5-6, 354-355, Dec. 2020.
11. Hirokazu Miki, 悦子 李, 佃 恵里加, 小田 直輝, 瀧本 朋美, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Daratumumab投与による輸血関連検査への影響とその対策,
Shikoku Acta Medica, Vol.76, No.5-6, 341, Dec. 2020.
12. Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Hirokazu Miki, 小田 明日香, Takeshi Harada, Ryohei Sumitani, Masahiro Oura, Kumiko Kagawa, Hirofumi Tenshin, Jumpei Teramachi, Masaki Ri, Shinsuke Iida and Masahiro Abe :
Immediate accumulation of anti-apoptotic PIM2 in myeloma cells by proteasome inhibitors,
第82回日本血液学会学術集会, Oct. 2020.
13. Hirofumi Tenshin, Mohannad Ashtar, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
抗腫瘍薬が誘導するROSは破骨細胞分化を促進する:Xanthine oxidase阻害剤febuxostatの治療効果.,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 148, Oct. 2020.
14. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Versatile anti-myeloma effects by elotuzumab: impact on γδT cells and osteoclasts,
The 82nd Annual Meeting of Japanese Soceity of Hematology, Oct. 2020.
15. Hirofumi Tenshin, アシテル モハナッド, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Sou Shimizu, 比嘉 佳基, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
抗腫瘍薬が誘導するROSは破骨細胞分化を促進する Xanthine oxidase阻害剤febuxostatの治療効果,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 148, Oct. 2020.
16. Masahiro Oura, Shingen Nakamura, 堀 太貴, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Tomoko Kobayashi, Takeshi Oya and Masahiro Abe :
結節性紅斑と悪性腫瘍関連血球貪食症候群を惹起した骨髄異形成症候群の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1542, Oct. 2020.
17. 中村 昌史, Hirokazu Miki, Masahiro Oura, 川田 知代, 堀 太貴, 村井 純平, Ryohei Sumitani, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, 菅崎 幹樹, 徳永 尚樹, Akishige Ikegame, 森下 英理子 and Masahiro Abe :
クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1537-1538, Oct. 2020.
18. 山崎 佳那子, 祖川 麻衣子, Kazutoshi Murao, Yoshiaki Kubo, Masahiro Oura, Takeshi Harada, Shingen Nakamura and Kumiko Kagawa :
骨髄異形成症候群の患者に生じた晩発性皮膚ポルフィリン症の1例,
The Nishinihon Journal of Dermatology, Vol.82, No.3, 238-239, Jun. 2020.
19. Kotaro Tanimoto, Masahiro Hiasa, Akihiko Iwasa, Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masami Iwasa, 小田 明日香, 曾我部 公子, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる.,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, Oct. 2019.
20. 谷本 幸太朗, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masami Iwasa, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる,
第37回日本骨代謝学会学術集会, Oct. 2019.
21. 安宅 克博, Shingen Nakamura, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Yasuhiko Nishioka and Masahiro Abe :
長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例,
第120回日本内科学会四国地方会, May 2019.
22. Takeshi Harada, Oda Asuka, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Masami Iwasa, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Teru Hideshima, Anderson C. Kenneth and Masahiro Abe :
The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells,
The 44th Annual Meeting of the Japanese Society of Myeloma, May 2019.
23. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction,
第80回日本血液学会学術集会, Oct. 2018.
24. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果,
第80回日本血液学会学術集会, Oct. 2018.
25. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, 前田 悠作, 高橋 真美子, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Amplification of the IFN- γ -STAT1- PD-L1 pathway in myeloma cells by panobinostat,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
26. Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Hirokazu Miki and Masahiro Oura :
MDS・発作性夜間血色素尿症を合併する胃癌に対する手術が安全に施行可能であった1例,
第118回日本外科学会定期学術集会, Apr. 2018.
27. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.

Et cetera, Workshop:

1. 岩脇 文香, 山﨑 佳那子, 中島 美世, Kazutoshi Murao, Yoshiaki Kubo and Masahiro Oura :
シアナミドによる薬疹を契機に丘疹-紅皮症を生じたHTLV-1キャリアの1例,
第73回日本皮膚科学会西部支部学術大会, Oct. 2021.